Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series

    Hyun Sun Park, Minwoo Kim, Ji Su Lee, Hyun‐Sun Yoon, Chul Huh, Oh Sang Kwon, Soyun Cho
    Image of study
    TLDR Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
    The study reported on the effectiveness of oral tofacitinib in 32 Korean patients with moderate-to-severe alopecia areata who had not responded to other treatments. It found that 75% of the patients saw hair regrowth, with 56.3% achieving 50% hair regrowth within 3 months and 28.1% achieving 90% hair regrowth within 6 months. Tofacitinib was well tolerated without serious side effects. The study concluded that tofacitinib is effective and safe for treating refractory moderate-to-severe alopecia areata in Korean patients, although ongoing treatment is necessary to maintain results. Further studies were recommended to determine the optimal dosage and treatment duration.
    View this study on doi.org →

    Cited in this study

    Related